Preliminary details of the deal, reported by EndPoints News<\/a>, indicate that Novo Nordisk, the maker of GLP-1s Ozempic and Wegovy, could offer the lowest dose of Wegovy through TrumpRx<\/a> for as little as $149. In exchange, the government would extend Medicare coverage for Wegovy for weight loss purposes. <\/p>\n Eli Lilly, the maker of Zepbound, could similarly offer a starting dose of the drug for $299 \u2013 $50 less than the current direct-to-consumer price \u2013 and Medicare would cover it for weight loss. <\/p>\n Ozempic, which Medicare and Medicaid cover for diabetes, could also be offered on TrumpRx, the planned government website that will sell prescriptions directly to consumers for a discounted rate. <\/p>\n The potential deal, which could be finalized as soon as this week, according to the Wall Street Journal<\/a> and Washington Post<\/a>, is part of Trump\u2019s efforts to lower drug prices for people in the U.S. <\/p>\n open image in gallery<\/p>\n Popular weight loss medications such as Wegovy, Ozempic and Zepbound could be offered for as little as $149 per month under new preliminary agreement (Getty Images)<\/p>\n White House spokesperson Kush Desai said in a statement, \u201cDiscussion about deals that have not been officially announced by the Administration should be regarded as speculation.\u201d<\/p>\n White House Press Secretary Karoline Leavitt said during her press briefing Tuesday that she wouldn\u2019t \u201cget ahead\u201d of any future announcements but emphasized the president is \u201ccommitted to bringing down the price of drugs.\u201d<\/p>\n Part of the anticipated deal also includes Eli Lilly obtaining a voucher from the Food and Drug Administration that would expedite review of its weight-loss pill, Orforglipron \u2013 which is currently undergoing testing, with the drug maker offering it on TrumpRx once it\u2019s approved. <\/p>\n Millions of Americans utilize weight-loss drugs, with recent health surveys<\/a> suggesting 12 percent of adults have used GLP-1s at some point.<\/p>\n People in the United States pay three times more for prescription medications than other countries in the Organization for Economic Cooperation and Development pay. That is, in part, because the government does not regulate price control, and its complicated price negotiation process gives drug makers the right to set prices. <\/p>\n open image in gallery<\/p>\n In May, Trump said he would begin negotiating with drug makers to obtain favorable prices for prescription medications (Getty)<\/p>\n Trump has signed a series of executive orders aiming to reduce drug costs for people in the U.S. through his \u201cmost favored nation\u201d policy, which intends to lower prices by 59 percent or more. He has also threatened 100 percent tariffs on pharmaceutical companies<\/a> unless they build a manufacturing plant in the U.S. <\/p>\n![\"Popular](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2025\/11\/GettyImages-2150033203.jpg\")
<\/p>\n![\"In](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2025\/11\/President-Trump-Delivers-An-Announcement-From-The-Oval-Office-jt9qb1xq.jpeg\")
<\/p>\n